OMEROS CORP (OMER)
OMEROS CORP (OMER) from its SEC filings: 2020 revenue $73.8 million (-34% vs the year before), net margin -187%, free cash flow -$100.4 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2020) | $73.8 million |
| Revenue growth | -34% |
| Net income | -$138.1 million |
| Net margin | -187.0% |
| Free cash flow | -$100.4 million |
| Diluted EPS | $-2.41 |
| Cash | $2.0 million |
| Long-term debt | $131.7 million |
| Share count, 1 year | +6% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.